( June 18, 2026, 9:03 AM EDT) -- SAN FRANCISCO — A telehealth company and a pharmacy that sell a compounded version of tirzepatide, a U.S. Food and Drug Administration-approved drug for diabetes and weight loss, argue in a “targeted and limited” motion to dismiss a second amended complaint filed by Eli Lilly & Co. that the California federal court should dismiss the conspiracy claims....